Recent Transactions

30-Nov-18
$NA
United States flag
Target: 

Aisthesis

United States flag
Acquiror: 
NAPA Management Services Corporation

Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities

15-Aug-18
$3.9 billion
Canada flag
Target: 

Common shares and common share purchase warrants in Canopy Growth

United States flag
Acquiror: 
Constellation Brands

Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

10-Jan-17
$204 million
United States flag
Target: 

Derma Sciences, Inc.

United States flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
United States flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

United States flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

24-Nov-16
$NA
Israel flag
Target: 

Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.

Switzerland flag
Acquiror: 
Rivopharm SA

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA

23-Nov-16
$NA
Israel flag
Target: 

Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.

France flag
Acquiror: 
Arrow Generiques SAS

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

05-Oct-16
$775 million
U.K., Ireland flags
Target: 

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m) 

05-Oct-16
$NA
Israel flag
Target: 

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Accord Healthcare Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

28-Jul-16
$80 million
United States flag
Target: 

BioD, LLC

United States flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

28-Jun-16
$NA
Israel flag
Target: 

US rights to an authorized generic version of Adderall XR

United States flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR

28-Jun-16
$652 million
Israel flag
Target: 

US rights to 37 approved and 5 pipeline generic products

Australia flag
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

21-Jun-16
$586 million
Israel flag
Target: 

US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Impax Laboratories, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.

20-Jun-16
$NA
Israel flag
Target: 

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

16-Jun-16
$40 million
Israel flag
Target: 

US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

United States flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
United States flag
Target: 

Aegerion Pharmaceuticals

Canada flag
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
Israel flag
Target: 

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

India flag
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

04-May-16
$NA
United States flag
Target: 

Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

United States flag
Acquiror: 
Ligand Pharmaceuticals

Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs

19-Apr-16
$NA
United States flag
Target: 

Total Care Medicaid Plan

United States flag
Acquiror: 
Molina Healthcare, Inc.

Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan

07-Mar-16
$NA
Germany flag
Target: 

Boehringer Ingelheim

United States flag
Acquiror: 
AbbVie

Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.

29-Oct-15
$275 million
United States flag
Target: 

Aesynt, Inc.

United States flag
Acquiror: 
Omnicell, Inc.

Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems

27-Jul-15
$40.5 billion
Ireland flag
Target: 

Allergan Generics

Israel flag
Acquiror: 
Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business

06-Jul-15
$910 million
United States flag
Target: 

Altegra Health, Inc.

United States flag
Acquiror: 
Emdeon Inc.

Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare

Pages

show all